近日，马斯克透露将于年内实现脑机接口产品量产，进一步"点燃"投资者对脑机接口板块的热情。与此同时，近一个月以来，国内脑机接口产业技术 突破、产品获批等捷报频传，为脑机接口产业蓬勃发展注入强信心。 板块热度高企之际，多家A股上市公司通过公告、投资者互动平台，紧急回应自身在脑机接口领域的业务进展。此外，也有上市公司积极透露脑机接 口布局新动态，从技术渗透、合作研发、战略投资等进展中，可看出各家公司脑机接口业务的"含金量"。 1月6日，脑机接口板块再度掀起"涨停潮"，其中倍益康继续"30cm"涨停，两日累计涨幅高达69%。伟思医疗、翔宇医疗、三博脑科、爱朋医疗、熵基 科技、美好医疗、麦澜德、谱尼测试、创新医疗等相继涨停。 | | 名称 | 涨幅号 | 现价 | | --- | --- | --- | --- | | 1 | 倍益康 | +29.98% | 58.44 | | 2 | 伟思医疗 | +20.01% | 69.70 | | 3 | 三博脑科 | +20.01% | 84.94 | | 4 | 爱朋医疗 | +20.00% | 39.96 | | 5 | 翔宇医疗 | +20.00% | 87.12 | ...

Group 1: Company Overview and Event Details - The investor relations activity was conducted as a live performance, showcasing the subsidiary Boling Brain Machine's introduction video and product demonstrations [2] - The event took place on September 25, 2025, at the Innovation Medical Hangzhou branch [2] Group 2: Product Features and Clinical Testing - Boling Brain Machine products are designed to be lightweight, user-friendly, and simple to operate, utilizing brain-machine interface technology to enhance patient rehabilitation [3] - Over 100 patients have participated in multi-center clinical tests, showing significant improvements in Fugl-Meyer scores for both newly diagnosed and long-term stroke patients [3][4] Group 3: Product Specifications and Future Developments - The C-end product weighs 1.5 kg and has a battery life of approximately 6 hours per battery, with two batteries included [3] - Future products include a dexterous hand for fine motor control and a pneumatic glove for gross motor actions, with ongoing research into invasive technology [4] Group 4: Economic Impact and Cost Savings - The C-end product can save families between 40,000 to 60,000 CNY annually by reducing the need for full-time caregivers [6] - Traditional rehabilitation costs can reach 65,000 CNY per year, while the Boling Brain Machine allows for home-based training, significantly lowering expenses [6] Group 5: Company Ownership and Market Position - The company holds a 68.356% stake in Boling Brain Machine, which is included in the consolidated financial statements [6]